SBIR/STTR Research Award

A Web-Enabled Database for Rapid Metagenomic Biocatalyst Discovery and Validation

Award identifier 2e403357e60240ffc5c7f37419ab7c797bf6ab886b4180698756fcc540676f98Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$965,675

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Radiant Genomics, Inc.
Proposal award date
2016-04-01
Contract end date
2015-05-31
UEI
QG8GZKZTMLM6
Solicitation number
PA14-071
Topic code
300

Research abstract

DESCRIPTION provided by applicant Enzyme biocatalysis plays an important role in pharmaceutical synthesis as it can afford precise control over stereochemistry while achieving many conversions under physiological conditions These benefits can both lower manufacturing costs and reduce environmental impact by eliminating solvent and heavy metal catalyst steps in a synthetic strategy Some recent examples of this include the enzyme catalyzed synthesis of the antidiabetic medication sitagliptin and the biomanufacturing of the antimalarial medication artemisinin Efficient enzyme discovery engineering and validation methods are required as the foundation of these efforts As organisms occupy diverse environments enzymes involved in identical conversions often possess dramatically different catalytic capacity and can harbor auxiliary domains which are critical for performance As a result it is has been routinely shown that broadening search efforts by drawing from diverse source organisms is the most efficient strategy for exploring catalytic fitness landscapes Due to the cost and time associated with accessing through DNA synthesis large numbers of enzyme variants researchers typically focus on testing a subselection of variants which have been previously characterized or those that are easy to obtain This approach is fundamentally limited as the overwhelming majority of available biocatalysts have not been studied in detail due to cultivation bottlenecks and there are no robust methods of predicting enzyme activity from primary sequence To address this limitation we propose to create a platform in which all computationally identified enzyme variants in a database search can be immediately isolated engineered and delivered to end users through a publicly available bioinformatics and LIMS driven automation platform Our strategy is x less expensive while being up to x faster than current DNA synthesis theoretical limits The platform is built upon a massive metagenomic library the largest reported in the world which overcomes the primary limitation of studying enzymes from cultivated sources This collection contains several orders of magnitude greater enzyme diversity than can be found in culture collections To populate the database we will apply our patented high efficiency sequencing method to our metagenomic library generating an unprecedented data set containing an N of andgt kb End users will be able to search and identify enzyme variants in this dataset and both native sequences and combinatorial libraries of variants can be retrieved produced and automatically delivered to end users in less than a week and for far less cost than DNA synthesis Overall this system comprises an end to end rapid biocatalyst discovery engineering and delivery system that will be a powerful resource for end users in basic research and industrial biotechnology PUBLIC HEALTH RELEVANCE The antimalarial medication artemisinin and the enzyme catalyzed synthesis of the antidiabetic medication sitagliptin are two prominent successes of bio based manufacturing of therapeutics In order for biomanufacturing to succeed consistently enzymes in the synthesis pathway must be extremely fast and efficient in order to produce the target molecules at cost effective yields yet the available choices for many of these pathway enzymes are very limited and slow We propose to sequence the largest and most diverse metagenomic library reported to date and build a web accessible platform that will provide researchers access to orders of magnitude more enzyme diversity to choose from when building out biomanufacturing pathways

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2013–2016). Reported award amounts total $3,402,238. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.